Atlas Trials

The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

Clinical trial NCT06656234 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06656234
Sponsor
Ruijin Hospital
Status
NOT_YET_RECRUITING
Study type
OBSERVATIONAL
Diffuse Large B Cell Lymphoma (DLBCL)
Start date
2024-10-30
Primary completion
2027-09-15
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.